Interleukin Genetics Nearly Doubles Revenues in Q4 | GenomeWeb

NEW YORK (GenomeWeb News) — Interleukin Genetics said after the close of market Thursday that its fourth quarter revenues nearly doubled year over year on increased royalty income and genetic testing revenue through the Amway Global sales channel.

Revenues for the three months ended Dec. 31, 2013, were $671,000 compared to $339,000 in the year-ago period. Genetic testing service revenue totaled $424,000 in the quarter, up from $317,000 in Q4 2012, while other revenues jumped to $247,000 from $22,000 in the prior-year period.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: Plasmodium knowlesi population structure, 'pre-adaptations' in algal ancestors of land plants, and more.

Replication studies that don't quite reflect the original findings underscore the need to better share data, the Wall Street Journal reports.

About two-thirds of proposals to work with select agents are denied — though most proposals that come in don't meet the definition of a restricted experiment, according to an analysis by the Centers for Disease Control and Prevention.

Researchers examine plant and human DNA found on the Shroud of Turin.

Sponsored by

This webinar will discuss the benefits of a rapid targeted next-generation sequencing (TNGS) panel, using dried blood spots, for second-tier newborn metabolic and hearing loss screening and its immediate utility for high-risk diagnostic testing in the neonatal intensive care unit. 

Sponsored by

This webinar will focus on a range of research and clinical applications enabled by improvements in mate pair technology for whole genome sequencing. 

Sponsored by
Oracle Health Sciences

Brian Wells of Penn Medicine will detail how his team's "PennOmics" integrated healthcare data warehouse accelerates clinical trial recruitment at the point of care, accepts data from wearables, and does it all in a secure, HIPAA- and research-compliant fashion.